Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinoporphyrin sodium photodynamic therapy for early esophageal cancer and locally recurrent/residual esophageal cancer after radiotherapy or chemoradiotherapy
CTR20222704Phase 2Active
- Sponsor
- Qinglong High-Tech
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cosiporfin sodium in esophageal cancer, esophagogastric junction cancer, sponsored by Qinglong High-Tech. Started Apr 2023; status: active.
02
Drugs
cosiporfin sodium
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on CTR20222704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222704.